Clinical Trials

1,118 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04697628 2026-02-24

innovaTV 301

502 enrolled 18 charts 1 FDA

Gynecologic

Uterine Cervical Neoplasms

NCT05104866 2026-02-04

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

732 enrolled 22 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04999969 2026-02-03

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

Phase 2 Active not recruiting

126 enrolled 30 charts

Locally Advanced or Metastatic Solid Tumours

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

1,126 enrolled 52 charts

Urothelial Cancer

NCT03377491 2026-01-21

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

571 enrolled 22 charts

Pancreas Adenocarcinoma

NCT02998528 2026-01-06

CheckMate 816

505 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung

NCT04182204 2025-12-22

POLARGO

270 enrolled 36 charts

Lymphoid

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT05147272 2025-12-05

Study of RP-6306 With Gemcitabine in Advanced Solid Tumors

Phase 1 Terminated

67 enrolled 22 charts

Adult Solid Tumor

NCT03193190 2025-11-21

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

341 enrolled 28 charts

Pancreatic Adenocarcinoma

NCT03371017 2025-11-12

IMpassion132

595 enrolled 37 charts

Breast

Triple Negative Breast Neoplasms

NCT04003610 2025-11-04

Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)

Phase 2 Terminated

7 enrolled 10 charts

Acrocephalosyndactylia, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT02477826 2025-10-30

CheckMate 227

2,747 enrolled 21 charts 2 FDA

BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Carcinoma, Non-Small-Cell Lung

NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

137 enrolled 31 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04497116 2025-10-21

TRESR

276 enrolled 33 charts

Advanced Solid Tumor

NCT03184870 2025-10-09

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

332 enrolled 44 charts

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

557 enrolled 22 charts 1 FDA

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT04659603 2025-10-01

CARMEN-BT01

Phase 2 Terminated

50 enrolled 20 charts

BreastGastrointestinal

Breast Cancer Metastatic

NCT04887831 2025-09-08

PRESERVE3

Phase 2 Terminated

92 enrolled 24 charts

BreastGastrointestinalSarcoma

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05092360 2025-08-28

ARTISTRY-7

Phase 3 Terminated

456 enrolled 19 charts

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

94 enrolled 28 charts

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT02711553 2025-08-03

A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer

Phase 2 Active not recruiting

309 enrolled 22 charts

GastrointestinalGenitourinaryThoracic

Biliary Tract Neoplasms, Neoplasm Metastasis

NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Phase 1 Completed

185 enrolled 28 charts

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

Phase 1 Completed

56 enrolled 19 charts

GastrointestinalGenitourinaryLymphoidThoracic

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT00981058 2025-06-18

SQUIRE

1,093 enrolled 24 charts

Carcinoma, Non-Small-Cell Lung

NCT04223856 2025-06-13

EV-302

886 enrolled 12 charts 1 FDA

Urothelial Cancer

NCT02953509 2025-05-29

Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

178 enrolled 33 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT04068896 2025-05-29

Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy

DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

89 enrolled 21 charts

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03710876 2025-05-20

INFINITE

Other solid neoplasmThoracic

53 enrolled 23 charts

Mesothelioma, Malignant

NCT01746979 2025-05-11

MAESTRO

693 enrolled 8 charts

Neoplasm Metastasis, Pancreatic Neoplasms

NCT02047500 2025-05-11

Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer

Phase 1 Terminated

19 enrolled 6 charts

Pancreatic Neoplasms

NCT01834235 2025-05-07

QUILT-3.010: A Study of Gemcitabine and Nab-paclitaxel With or Without NPC-1C to Treat Patients With Pancreatic Cancer

Phase 1/2 Terminated

81 enrolled 13 charts

Pancreatic cancer, adult, Pancreatic Neoplasms

NCT04003636 2025-04-23

KEYNOTE-966

1,069 enrolled 19 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04924062 2025-04-17

MK-3475-966

158 enrolled 19 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Bile Duct Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT02650804 2025-03-26

BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients

Phase 2 Completed

45 enrolled 14 charts

EndocrineGynecologicNETThoracic

Neoplasms, Pancreatic Neoplasms

NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Phase 2 Completed

139 enrolled 14 charts

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT02807636 2025-02-24

IMvigor130

1,213 enrolled 35 charts

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02576574 2025-01-31

Avelumab in First-line NSCLC (JAVELIN Lung 100)

1,214 enrolled 40 charts

Carcinoma, Non-Small-Cell Lung

NCT03924986 2025-01-31

RATIONALE-309

263 enrolled 19 charts

Head & Neck

Nasopharyngeal Neoplasms, Recurrence

NCT02240238 2025-01-22

Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer

119 enrolled 24 charts